Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Zhongyuan Union Cell & Gene Engineering Cash Conversion Cycle Related Terms
Zhongyuan Union Cell & Gene Engineering Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering Cash Conversion Cycle Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Cash Conversion Cycle falls into.
Zhongyuan Union Cell & Gene Engineering Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Cash Conversion Cycle of 297.25 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors.
Is Zhongyuan Union Cell & Gene Engineering's Cash Conversion Cycle too high?
Zhongyuan Union Cell & Gene Engineering's current Cash Conversion Cycle is 297.25. The Biotechnology industry median Cash Conversion Cycle is 103.69. Zhongyuan Union Cell & Gene Engineering's value of 297.25 is 186.7% above this industry median. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Cash Conversion Cycle compare to VRTX and REGN?
Zhongyuan Union Cell & Gene Engineering's Cash Conversion Cycle of 297.25 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Zhongyuan Union Cell & Gene Engineering's value of 297.25 is 186.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current Cash Conversion Cycle of 297.25 is 186.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current Cash Conversion Cycle is 297.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.36, compared to a current price of ¥17.92 — trading 12% below its estimated fair value. The current Cash Conversion Cycle is 297.25 and 186.7% above the Biotechnology industry median of 103.69. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Cash Conversion Cycle is 297.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥17.92 is trading 12% below its estimated GF Value™ of ¥20.36.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
Cash Conversion Cycle: 297.25
GF Value™: ¥20.36 vs. price of ¥17.92 (12% below fair value)
Industry Position: 186.7% above the Biotechnology median
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Business Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score
Get the complete analysis for SHSE:600645
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
